Profitability ratios measure the company ability to generate profitable sales from its resources (assets).
Paying users area
Try for free
Bristol-Myers Squibb Co. pages available for free this week:
- Balance Sheet: Liabilities and Stockholders’ Equity
- Common-Size Income Statement
- Analysis of Liquidity Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Enterprise Value to EBITDA (EV/EBITDA)
- Capital Asset Pricing Model (CAPM)
- Present Value of Free Cash Flow to Equity (FCFE)
- Debt to Equity since 2005
- Total Asset Turnover since 2005
- Analysis of Revenues
The data is hidden behind: . Unhide it.
Get 1-month access to Bristol-Myers Squibb Co. for $24.99, or
get full access to the entire website for at least 3 months from $62.19.
This is a one-time payment. There is no automatic renewal.
We accept:
Profitability Ratios (Summary)
Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
Profitability ratio | Description | The company |
---|---|---|
Gross profit margin | Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. | Bristol-Myers Squibb Co. gross profit margin ratio deteriorated from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023. |
Operating profit margin | A profitability ratio calculated as operating income divided by revenue. | Bristol-Myers Squibb Co. operating profit margin ratio deteriorated from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023. |
Net profit margin | An indicator of profitability, calculated as net income divided by revenue. | Bristol-Myers Squibb Co. net profit margin ratio improved from Q2 2023 to Q3 2023 but then slightly deteriorated from Q3 2023 to Q4 2023 not reaching Q2 2023 level. |
Profitability ratio | Description | The company |
---|---|---|
ROE | A profitability ratio calculated as net income divided by shareholders’ equity. | Bristol-Myers Squibb Co. ROE improved from Q2 2023 to Q3 2023 but then slightly deteriorated from Q3 2023 to Q4 2023. |
ROA | A profitability ratio calculated as net income divided by total assets. | Bristol-Myers Squibb Co. ROA improved from Q2 2023 to Q3 2023 but then deteriorated significantly from Q3 2023 to Q4 2023. |
Gross Profit Margin
Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||
Gross margin | ||||||||||||||||||||||||||
Revenues | ||||||||||||||||||||||||||
Profitability Ratio | ||||||||||||||||||||||||||
Gross profit margin1 | ||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||
Gross Profit Margin, Competitors2 | ||||||||||||||||||||||||||
AbbVie Inc. | ||||||||||||||||||||||||||
Amgen Inc. | ||||||||||||||||||||||||||
Eli Lilly & Co. | ||||||||||||||||||||||||||
Gilead Sciences Inc. | ||||||||||||||||||||||||||
Johnson & Johnson | ||||||||||||||||||||||||||
Merck & Co. Inc. | ||||||||||||||||||||||||||
Pfizer Inc. | ||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q4 2023 Calculation
Gross profit margin = 100
× (Gross marginQ4 2023
+ Gross marginQ3 2023
+ Gross marginQ2 2023
+ Gross marginQ1 2023)
÷ (RevenuesQ4 2023
+ RevenuesQ3 2023
+ RevenuesQ2 2023
+ RevenuesQ1 2023)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
Profitability ratio | Description | The company |
---|---|---|
Gross profit margin | Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. | Bristol-Myers Squibb Co. gross profit margin ratio deteriorated from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023. |
Operating Profit Margin
Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||
Operating income (loss) | ||||||||||||||||||||||||||
Revenues | ||||||||||||||||||||||||||
Profitability Ratio | ||||||||||||||||||||||||||
Operating profit margin1 | ||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||
Operating Profit Margin, Competitors2 | ||||||||||||||||||||||||||
AbbVie Inc. | ||||||||||||||||||||||||||
Amgen Inc. | ||||||||||||||||||||||||||
Eli Lilly & Co. | ||||||||||||||||||||||||||
Gilead Sciences Inc. | ||||||||||||||||||||||||||
Johnson & Johnson | ||||||||||||||||||||||||||
Merck & Co. Inc. | ||||||||||||||||||||||||||
Pfizer Inc. | ||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q4 2023 Calculation
Operating profit margin = 100
× (Operating income (loss)Q4 2023
+ Operating income (loss)Q3 2023
+ Operating income (loss)Q2 2023
+ Operating income (loss)Q1 2023)
÷ (RevenuesQ4 2023
+ RevenuesQ3 2023
+ RevenuesQ2 2023
+ RevenuesQ1 2023)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
Profitability ratio | Description | The company |
---|---|---|
Operating profit margin | A profitability ratio calculated as operating income divided by revenue. | Bristol-Myers Squibb Co. operating profit margin ratio deteriorated from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023. |
Net Profit Margin
Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||
Net earnings (loss) attributable to BMS | ||||||||||||||||||||||||||
Revenues | ||||||||||||||||||||||||||
Profitability Ratio | ||||||||||||||||||||||||||
Net profit margin1 | ||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||
Net Profit Margin, Competitors2 | ||||||||||||||||||||||||||
AbbVie Inc. | ||||||||||||||||||||||||||
Amgen Inc. | ||||||||||||||||||||||||||
Eli Lilly & Co. | ||||||||||||||||||||||||||
Gilead Sciences Inc. | ||||||||||||||||||||||||||
Johnson & Johnson | ||||||||||||||||||||||||||
Merck & Co. Inc. | ||||||||||||||||||||||||||
Pfizer Inc. | ||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q4 2023 Calculation
Net profit margin = 100
× (Net earnings (loss) attributable to BMSQ4 2023
+ Net earnings (loss) attributable to BMSQ3 2023
+ Net earnings (loss) attributable to BMSQ2 2023
+ Net earnings (loss) attributable to BMSQ1 2023)
÷ (RevenuesQ4 2023
+ RevenuesQ3 2023
+ RevenuesQ2 2023
+ RevenuesQ1 2023)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
Profitability ratio | Description | The company |
---|---|---|
Net profit margin | An indicator of profitability, calculated as net income divided by revenue. | Bristol-Myers Squibb Co. net profit margin ratio improved from Q2 2023 to Q3 2023 but then slightly deteriorated from Q3 2023 to Q4 2023 not reaching Q2 2023 level. |
Return on Equity (ROE)
Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||
Net earnings (loss) attributable to BMS | ||||||||||||||||||||||||||
Total BMS shareholders’ equity | ||||||||||||||||||||||||||
Profitability Ratio | ||||||||||||||||||||||||||
ROE1 | ||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||
ROE, Competitors2 | ||||||||||||||||||||||||||
AbbVie Inc. | ||||||||||||||||||||||||||
Amgen Inc. | ||||||||||||||||||||||||||
Eli Lilly & Co. | ||||||||||||||||||||||||||
Gilead Sciences Inc. | ||||||||||||||||||||||||||
Johnson & Johnson | ||||||||||||||||||||||||||
Merck & Co. Inc. | ||||||||||||||||||||||||||
Pfizer Inc. | ||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q4 2023 Calculation
ROE = 100
× (Net earnings (loss) attributable to BMSQ4 2023
+ Net earnings (loss) attributable to BMSQ3 2023
+ Net earnings (loss) attributable to BMSQ2 2023
+ Net earnings (loss) attributable to BMSQ1 2023)
÷ Total BMS shareholders’ equity
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
Profitability ratio | Description | The company |
---|---|---|
ROE | A profitability ratio calculated as net income divided by shareholders’ equity. | Bristol-Myers Squibb Co. ROE improved from Q2 2023 to Q3 2023 but then slightly deteriorated from Q3 2023 to Q4 2023. |
Return on Assets (ROA)
Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||
Net earnings (loss) attributable to BMS | ||||||||||||||||||||||||||
Total assets | ||||||||||||||||||||||||||
Profitability Ratio | ||||||||||||||||||||||||||
ROA1 | ||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||
ROA, Competitors2 | ||||||||||||||||||||||||||
AbbVie Inc. | ||||||||||||||||||||||||||
Amgen Inc. | ||||||||||||||||||||||||||
Eli Lilly & Co. | ||||||||||||||||||||||||||
Gilead Sciences Inc. | ||||||||||||||||||||||||||
Johnson & Johnson | ||||||||||||||||||||||||||
Merck & Co. Inc. | ||||||||||||||||||||||||||
Pfizer Inc. | ||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q4 2023 Calculation
ROA = 100
× (Net earnings (loss) attributable to BMSQ4 2023
+ Net earnings (loss) attributable to BMSQ3 2023
+ Net earnings (loss) attributable to BMSQ2 2023
+ Net earnings (loss) attributable to BMSQ1 2023)
÷ Total assets
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
Profitability ratio | Description | The company |
---|---|---|
ROA | A profitability ratio calculated as net income divided by total assets. | Bristol-Myers Squibb Co. ROA improved from Q2 2023 to Q3 2023 but then deteriorated significantly from Q3 2023 to Q4 2023. |